| Symbol | CTOR |
|---|---|
| Name | CITIUS ONCOLOGY, INC. |
| Sector | HEALTH CARE |
| Region | North America |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Address | 420 LEXINGTON AVE,SUITE 2446, NEW YORK, New York, 10017, United States |
| Telephone | (908) 967-6677 |
| Fax | — |
| — | |
| Website | https://www.citiusonc.com |
| Incorporation | UNDEFINED |
| Incorporated On | — |
| Employees | — |
| Fiscal Year | — |
| Public Since | — |
| Exchanges | NASDAQ |
| Auditor | — |
| Audit Status | NOT PROVIDED |
| Reporting Status | — |
| CIK | 0001851484 |
| Description | Citius Oncology will serve as a platform to develop and commercialize novel targeted oncology therapies. In August 2024, its primary asset, LYMPHIR, was approved by the FDA for the treatment of adults with relapsed or refractory CTCL who had had at least one prior systemic therapy. Management estimates the initial market for LYMPHIR currently exceeds 400 million, is growing, and is underserved by existing therapies. Robust intellectual property protections that span orphan drug designation, complex technology, trade secrets and pending patents for immuno-oncology use as a combination therapy with checkpoint inhibitors would further support Citius Oncology s competitive positioning. Citius Oncology is a publicly traded subsidiary of Citius Pharmaceuticals. Additional info from NASDAQ: |
New Form EFFECT - CITIUS ONCOLOGY, INC. <b>Filed:</b> 2026-06-05 <b>AccNo:</b> 9999999995-26-001912 <b>Size:</b> 1 KB
Read moreNew Form 424B3 - CITIUS ONCOLOGY, INC. <b>Filed:</b> 2026-06-01 <b>AccNo:</b> 0001213900-26-063546 <b>Size:</b> 120 KB
Read moreNew Form DEF 14C - CITIUS ONCOLOGY, INC. <b>Filed:</b> 2026-05-29 <b>AccNo:</b> 0001213900-26-062911 <b>Size:</b> 98 KB
Read moreNew Form 424B3 - CITIUS ONCOLOGY, INC. <b>Filed:</b> 2026-05-22 <b>AccNo:</b> 0001213900-26-060571 <b>Size:</b> 386 KB
Read moreNew Form PRE 14C - CITIUS ONCOLOGY, INC. <b>Filed:</b> 2026-05-19 <b>AccNo:</b> 0001213900-26-059053 <b>Size:</b> 98 KB
Read more(30% Negative) CITIUS ONCOLOGY, INC. (CTOR) Reports Q2 2026 Financial Results
Read moreNew Form SCHEDULE 13G/A - CITIUS ONCOLOGY, INC. <b>Filed:</b> 2026-05-15 <b>AccNo:</b> 0001172661-26-002138 <b>Size:</b> 10 KB
Read moreNew Form 424B3 - CITIUS ONCOLOGY, INC. <b>Filed:</b> 2026-05-06 <b>AccNo:</b> 0001213900-26-052840 <b>Size:</b> 1 MB
Read more(99% Neutral) CITIUS ONCOLOGY, INC. (CTOR) Announces Business Combination
Read moreNew Form 424B3 - CITIUS ONCOLOGY, INC. <b>Filed:</b> 2026-05-05 <b>AccNo:</b> 0001213900-26-052124 <b>Size:</b> 300 KB
Read more